Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug Therapy01:28

Drug Therapy

The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Psychosis: Goals of Pharmacotherapy01:26

Psychosis: Goals of Pharmacotherapy

Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation. For...
Psychosis and Antipsychotic Drugs: Overview01:28

Psychosis and Antipsychotic Drugs: Overview

The term "psychosis" refers to a spectrum of mental disorders characterized by abnormal thoughts, perceptions, and behaviors. It can manifest as mood disorders, dementia, delirium with psychotic features, substance-induced psychosis with psychotic features, brief psychotic disorder, delusional disorder, schizoaffective disorder, and schizophrenia. Among all these disorders, schizophrenia is the most common psychotic disorder, affecting 1% of the worldwide population. Psychotic symptoms in all...
Psychosis: Pathophysiology of Schizophrenia and Other Psychotic Disorders01:27

Psychosis: Pathophysiology of Schizophrenia and Other Psychotic Disorders

Schizophrenia is a neurodevelopmental disorder whose origins are rooted in complex genetic components. Despite our burgeoning understanding, the pathophysiology of this disorder remains incompletely deciphered.
Researchers have identified genetic factors that increase susceptibility to schizophrenia, underscoring the intricate interplay between genetics and environment in disease development. At the core of schizophrenia's pathophysiology is excessive dopaminergic neurotransmission within the...
Antidepressant Drugs: MAOIs and Other Agents01:23

Antidepressant Drugs: MAOIs and Other Agents

Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
Antipsychotic Drugs: Typical and Atypical Agents01:21

Antipsychotic Drugs: Typical and Atypical Agents

Antipsychotic drugs are classified into first-generation (typical) drugs including phenothiazines; and second-generation (atypical) drugs. Chlorpromazine hydrochloride (Thorazine), a phenothiazine derivative, broadly impacts the central, autonomic, and endocrine systems. This drug, along with typical agents like haloperidol (Haldol), primarily works by antagonizing D2 receptors, thus reducing dopaminergic neurotransmission. However, typical antipsychotics can cause side effects such as sedation...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Volume and Tempo: Cortical Excitability and Trial-to-Trial Consistency of Auditory Responses Distinguish Psychosis Biotypes.

Research square·2026
Same author

Mediodorsal and pulvinar thalamus reductions across the psychosis spectrum.

Schizophrenia research·2026
Same author

Network-targeted TMS modulates nicotine craving and default mode network connectivity in psychotic disorders.

Brain stimulation·2026
Same author

Medicinal Chemistry of Next Generation Vaccine Adjuvants.

Journal of medicinal chemistry·2026
Same author

The Future of <i>DSM</i>: Role of Candidate Biomarkers and Biological Factors.

The American journal of psychiatry·2026
Same author

Biomarker innovations in precision psychiatry diagnostics and treatment strategies.

European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology·2026

Related Experiment Video

Updated: Jul 6, 2026

HSV-Mediated Transgene Expression of Chimeric Constructs to Study Behavioral Function of GPCR Heteromers in Mice
07:30

HSV-Mediated Transgene Expression of Chimeric Constructs to Study Behavioral Function of GPCR Heteromers in Mice

Published on: July 9, 2016

Schizophrenia: moving beyond monoamine antagonists.

P Jeffrey Conn1, Carol Tamminga, Darryle D Schoepp

  • 1Vanderbilt University, Department of Pharmacology, Nashville, TN 37232, USA. jeff.conn@vanderbilt.edu

Molecular Interventions
|April 12, 2008
PubMed
Summary

New research explores novel treatments for schizophrenia beyond dopamine D2 receptor antagonists. Focusing on muscarinic, nicotinic, and glutamatergic pathways offers new hope for addressing negative and cognitive symptoms.

More Related Videos

Standardized Data Acquisition for Neuromelanin-Sensitive Magnetic Resonance Imaging of the Substantia Nigra
05:14

Standardized Data Acquisition for Neuromelanin-Sensitive Magnetic Resonance Imaging of the Substantia Nigra

Published on: September 8, 2021

Related Experiment Videos

Last Updated: Jul 6, 2026

HSV-Mediated Transgene Expression of Chimeric Constructs to Study Behavioral Function of GPCR Heteromers in Mice
07:30

HSV-Mediated Transgene Expression of Chimeric Constructs to Study Behavioral Function of GPCR Heteromers in Mice

Published on: July 9, 2016

Standardized Data Acquisition for Neuromelanin-Sensitive Magnetic Resonance Imaging of the Substantia Nigra
05:14

Standardized Data Acquisition for Neuromelanin-Sensitive Magnetic Resonance Imaging of the Substantia Nigra

Published on: September 8, 2021

Area of Science:

  • Neuroscience
  • Psychiatry
  • Pharmacology

Background:

  • Schizophrenia is a severe psychiatric disorder with positive, negative, and cognitive symptoms.
  • Early treatments focused on dopamine D2 receptor antagonists, primarily targeting positive symptoms.
  • Limited efficacy of traditional antipsychotics against negative and cognitive symptoms necessitates new therapeutic strategies.

Purpose of the Study:

  • To review emerging experimental approaches for schizophrenia treatment.
  • To highlight the role of non-monoamine receptor targets in addressing diverse symptom clusters.
  • To discuss novel drug entities and receptor subtype-specific targeting.

Main Methods:

  • Review of recent neuropharmacological and behavioral studies.
  • Analysis of emerging therapeutic targets beyond monoamine pathways.
  • Examination of novel drug entities targeting specific receptor subtypes.

Main Results:

  • New experimental approaches are identifying treatments for distinct schizophrenia symptom clusters.
  • Muscarinic, nicotinic, and glutamatergic signaling are key targets for novel therapies.
  • Fine-tuning pharmacological manipulation of specific receptor subtypes is advancing treatment development.

Conclusions:

  • Novel therapeutic strategies targeting non-monoamine receptors show promise for schizophrenia.
  • Focus on muscarinic, nicotinic, and glutamatergic systems offers potential for treating negative and cognitive symptoms.
  • Precision pharmacology targeting specific receptor subtypes represents the future of schizophrenia treatment.